Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Eugenio Arteaga is active.

Publication


Featured researches published by Eugenio Arteaga.


Annals of Internal Medicine | 1984

Aldosterone-Producing Adrenocortical Carcinoma: Preoperative Recognition and Course in Three Cases

Eugenio Arteaga; Edward G. Biglieri; Claudio E. Kater; José Manuel López; Morris Schambelan

Three patients with primary aldosteronism due to adrenocortical carcinoma were studied, two with hyperaldosteronism alone and one also with hypercortisolism; in the later stages all three had hypersecretion of glucocorticoid and androgenic hormones. Although clinical presentations were similar to those of patients with benign adenoma, all had significantly higher concentrations of deoxycorticosterone and aldosterone and more profound hypokalemia. Stimulation with adrenocorticotropin in two patients showed a good cortisol response but no aldosterone response. The circadian rhythm for cortisol was normal but absent for aldosterone and deoxycorticosterone. Sequential 24-hour circadian studies in one patient showed that as the disease progressed, corticosterone and finally cortisol lost their circadian rhythms. Treatment with spironolactone, mitotane, or aminoglutethimide had transient clinical effects. The patients died 2 to 13 years later.


Clinical Endocrinology | 1983

EFFECT OF THE COMBINATION OF DEXAMETHASONE AND SODIUM IPODATE ON SERUM THYROID HORMONES IN GRAVES' DISEASE

Eugenio Arteaga; José Manuel López; José Adolfo Rodriguez; P. Michaud; G. López

To investigate the effect of the combination of dexamethasone (Dex) and sodium ipodate (SI) on hyperthyroidism, we studied 24 patients with typical GRAVES disease, divided into four groups of six persons each. Three groups (Study I) were studied acutely (24 h) to determine the effects of Dex (5 mg every 12 h intramuscularly), SI (one oral dose of 3 g) and both drugs at the same doses, upon T4, T3, and rT3 at 0900 h before therapy was started and 24 h later. The group on Dex and that on SI had a similar T3 decrement of 25·9±4·0% and 35·8±5·0%, respectively, (P < 0·05), whereas the effect of both drugs combined was greater (64·2±3·6%; P<0·01, Dex, and P<0·01, SI, respectively). The increment of rT3 was markedly greater in those patients on SI than in those on Dex (561·3±149·2% and 58·9±11%, respectively, P<0·025). A fourth group (Study II) was studied for seven days while receiving both Dex (1 mg orally three times per day) and SI (500 mg orally three times per day). Both T4 (from 18·8 ± 1·1 to 13·1 ± 1·1 μg/dl, P < 0·02) and T3 (from 593 · 41 to 136·3 ± 12·7 ng/dl, P< 0·001) decreased at day 8. The initial brisk increment of rT3 at 24 h (808 ± 149%, P< 0·005) then diminished concomitantly with the fall of its precursor, T4. The pulse rate correlated with plasma T3 concentration (r= 0·67, P< 0·001) and varied from 104·7 ± 3·9 on day 1 to 77·3 ± 3·0 beats/min (P< 0·001) on day 4 and then remained stable. These results show that Dex and SI have potent inhibitory effects at the level of peripheral conversion of T4 and on the thyroid gland itself and that the combined use of these drugs significantly increases these effects. Considering the rapid clinical improvement of thyrotoxicosis achieved with both drugs, this regimen may be valuable in the initial treatment of some patients.


Journal of Endocrinological Investigation | 1990

Adrenal macrotumors diagnosed by computed tomography

José Manuel López; Carlos Fardella; Eugenio Arteaga; P. Michaud; José Adolfo Rodriguez; F. Cruz

Adrenal tumors larger than 6 cm are unusual but show a greater incidence of malignant etiologies than smaller adrenal tumors. The scarce information about adrenal macrotumors (AMT) induced us to study prospectively all patients who were seen in our clinic during the period 1984–1988 and were diagnosed by computed tomography (CT) to have an adrenal mass ≥ 6 cm. The clinical characteristics, including the main complaint, tumoral secretory activity, CT findings and histologic diagnosis from 18 patients are described; they represented a 0.3% of the total amount of abdominal CT studies performed. Seventy-two % of AMT resulted to be non Cortisol or catecholamines secreting masses, and from them, a 38% corresponded to malignant etiologies characterized by marked and rapid weight loss. Four out of five hormone secreting AMT corresponded to pheochromocytomas, while the fifth one resulted to be a bilateral macronodular hyperplasia secreting Cortisol. In two cases AMT did not correspond to a genuine adrenal mass, resulting to be a malignant histocytoma in one case and a hydatidic cyst in other one. When performed in two occasions, a percutaneous needle biopsy was a valuable diagnostic tool, permitting to diagnose a lymphoma and a tuberculoma. In conclusion: 1) AMT correspond mainly to non Cortisol or catecholamines secreting tumors, often malignant; 2) not all AMT diagnosed by CT correspond to true adrenal masses; 3) percutaneous needle biopsy can be a helpful procedure for diagnosing nonfunctioning solid AMT.


American Journal of Physiology-endocrinology and Metabolism | 1987

Adrenocortical hormone secretory response to chronic NH4Cl-induced metabolic acidosis

Morris Schambelan; Anthony Sebastian; B. A. Katuna; Eugenio Arteaga


Archives of Otolaryngology-head & Neck Surgery | 2007

Impact of Preoperative Ultrasonographic Staging of the Neck in Papillary Thyroid Carcinoma

Hernán E. González; Francisco Cruz; Andrés O’Brien; Ignacio Goñi; Augusto León; Raúl Claure; Mauricio Camus; Francisco José Suárez Domínguez; Lorena Mosso; Eugenio Arteaga; Gilberto González; José Manuel López; José Adolfo Rodriguez; Carmen A. Carrasco; Carlos E. Fardella


Hypertension | 1983

Studies of impaired aldosterone response to spironolactone-induced renin and potassium elevations in adenomatous but not hyperplastic primary aldosteronism.

Claudio E. Kater; Edward G. Biglieri; Morris Schambelan; Eugenio Arteaga


The Journal of Clinical Endocrinology and Metabolism | 2004

Novel intronic mutation of MEN1 gene causing familial isolated primary hyperparathyroidism.

Carmen A. Carrasco; Alexis A. González; Cristian A. Carvajal; Claudia Campusano; Eveline Oestreicher; Eugenio Arteaga; Nelson Wohllk; Carlos E. Fardella


The Journal of Clinical Endocrinology and Metabolism | 1991

A Prepubertal Surge of Thyrotropin Precedes an Increase in Thyroxine and 3,5,3′-Triiodothyronine in Normal Children

Michaud P; Arnaldo Foradori; José A. Rodríguez-Portales; Eugenio Arteaga; José Manuel López; Rafael Téllez


The Journal of Clinical Endocrinology and Metabolism | 1988

Zona Glomerulosa Function After Life-Long Suppression in Two Siblings With the Hypertensive Virilizing Form of Congenital Adrenal Hyperplasia

José Adolfo Rodríguez Portales; Eugenio Arteaga; José M. López Moreno; Edward G. Biglieri


Revista Medica De Chile | 1989

Síndrome de Cushing por hiperplasia suprarrenal macronodular independiente de ACTH: comunicación de un caso

Eugenio Arteaga; Daniel Mahana X.; Renato González; Pedro Martínez

Collaboration


Dive into the Eugenio Arteaga's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michaud P

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carlos E. Fardella

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

López Jm

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rodríguez Ja

University of California

View shared research outputs
Top Co-Authors

Avatar

Carmen A. Carrasco

Pontifical Catholic University of Chile

View shared research outputs
Top Co-Authors

Avatar

Daniel Mahana

Pontifical Catholic University of Chile

View shared research outputs
Researchain Logo
Decentralizing Knowledge